ALFA Finder
India's fastest NSE & BSE filing alerts on Telegram, filtered to the stocks you hold
Telegram alerts
alfafinder.com →
ALFA Filings
Every announcement, straight from the exchange
Reference market data from a third-party provider, updated daily. Not a valuation or a recommendation.
Announcement type
Time
37 announcements
Aarti Drugs disclosed that the US FDA inspected its subsidiary Pinnacle Life Science's Baddi plant on 2-6 November 2026 and issued three Form 483 observations. The company states there is no financial or operational impact.
Q2 FY27 consolidated revenue Rs 826.2 Cr (+27% YoY), EBITDA Rs 137.9 Cr (16.6% margin, +370 bps), PAT Rs 82.8 Cr (+83%). Specialty chemicals nearly doubled; formulations grew 58%.
Aarti Drugs reports Q2 FY27 revenue of ₹828.8 Crore and PAT of ₹82.8 Crore, up 83% YoY. Results reflect record quarterly EBITDA and margin expansion.
Aarti Drugs Ltd reported revenue from operations of ₹826.2 Cr (+26.6% YoY) and net profit of ₹82.8 Cr (+83.2% YoY) for Q2 FY27.
Aarti Drugs Ltd intimated BSE and NSE of a board meeting on November 3, 2026, to consider audited financial results for the quarter and half year ended September 30, 2026. Trading window remains closed until 48 hours after results declaration.
The company submitted its quarterly shareholding pattern as of September 30, 2026, in compliance with SEBI Listing Regulations.
Aarti Drugs has updated its list of authorized personnel for determining materiality of events and making stock exchange disclosures, effective October 1, 2026.
Aarti Drugs Ltd announced the retirement of Director Uday M. Patil and the appointment of new directors, including Adhish P. Patil as the Managing Director.
Aarti Drugs reports Q1 FY27 revenue of ₹704 Cr, up 19% YoY. Management focuses on scaling regulated market sales through high-margin formulations and oncology backward integration.
Aarti Drugs Limited conducted its 41st Annual General Meeting on September 26, 2026, to consider various ordinary and special business resolutions.
Aarti Drugs Ltd has issued a notice for its 41st Annual General Meeting scheduled for September 26, 2026. The agenda includes financial statements and director appointments.
Aarti Drugs has released its Annual Report for FY 2025-26 and notice for its 41st Annual General Meeting scheduled for September 26, 2026.
Aarti Drugs Limited board approved the Performance Stock Option Plan 2026. The plan involves granting up to 8,00,000 stock options to eligible employees, subject to shareholder approval.
Aarti Drugs Ltd scheduled a Board Meeting on August 27, 2026, to consider the 'Aarti Drugs Limited – Performance Stock Option Plan 2026'.
Aarti Drugs Ltd has submitted its quarterly shareholding pattern in compliance with Regulation 31(1)(b) of SEBI (LODR) Regulations for the quarter ended June 30, 2026.
Aarti Drugs disclosed that the Supreme Court dismissed the GST Department's Special Leave Petition, effectively disposing of the tax litigation matter in the company's favor.
The Supreme Court dismissed the GST Department's Special Leave Petition, favoring the company. This favorable order resolves the pending tax litigation regarding GST demands.
Aarti Drugs reported Q1 FY27 revenue of ₹703.6 Cr, up 19% YoY, with EBITDA rising 30% to ₹96.9 Cr. Strategy focuses on backward integration at Sayakha and USFDA-regulated market expansion.
Aarti Drugs reported Q1FY27 revenue of ₹703.6 Cr with 19% YoY growth. EBITDA rose 30% to ₹96.9 Cr, driven by volume growth and improved pricing realizations across API and Specialty Chemicals portfolios.
Aarti Drugs reported Q1 FY27 consolidated revenue of ₹703.6 crore and EBITDA of ₹96.9 crore, reflecting 19% and 30% YoY growth respectively.
Aarti Drugs Limited received a revocation order from the GPCB for its Sayakha plant, allowing continued operations. The company paid Rs. 0.102 Crore as interim compensation.
Aarti Drugs announced significant board changes, including the appointment of new Executive Directors, several re-appointments, and the resignation of directors Prakash M. Patil and Uday M. Patil.
Aarti Drugs Limited announced the retirement of MD & CEO Prakash M. Patil. The company appointed Rashesh C. Gogri as Chairman and Adhish P. Patil as Managing Director.
Aarti Drugs Ltd reported revenue from operations of ₹702.8 Cr (+19.0% YoY) and net profit of ₹50.1 Cr (-7.2% YoY) for Q1 FY27.
Aarti Drugs Limited has scheduled a board meeting for July 31, 2026, to consider and approve the financial results for the quarter ended June 30, 2026.
Aarti Drugs Ltd has filed its quarterly shareholding pattern for the period ending June 30, 2026, in compliance with SEBI regulations.
Aarti Drugs received a closure directive from GPCB for its Saykha manufacturing unit due to alleged non-compliances. The company is taking corrective measures for revocation.
Aarti Drugs' promoters disclosed that 6,41,814 and 5,97,957 shares are encumbered as of March 31 2026. The declaration complies with SEBI Takeover Regulation 31(4).
Promoters of Aarti Drugs Ltd reduced their shareholding from 55.70% to 54.43%. The disposal occurred via market sales between May 29 and June 24, 2025.
Aarti Drugs reported Q4 FY26 revenue of ₹721.1 Cr (up 6% YoY) with EBITDA margins at 13.4%. Management is transitioning from investment to an operational scale-up phase despite geopolitical headwinds.